Corcept Therapeutics Inc. (CORT) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy12 analystsWhat's happening with CORT
Price History
5-Year Weekly Candlestick Chart
Profile
Strong financial health; profitability, valuation and earnings quality lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (99th pct)0/25
- FCF yield (0.9%)5/25
- P/S (16.5x)5/25
- EV/EBIT (n/a)10/25
- Growth50/100 · Moderate
- Revenue CAGR (20.1%)25/25
- Net income CAGR (-3.0%)0/25
- EPS CAGR 5Y (-1.8%)0/25
- Fwd implied growth (322.3%)25/25
- Profitability18/100 · Weak
- ROIC (-2.2%)0/25
- ROE (7.4%)5/25
- Net margin (6.2%)13/25
- Operating margin (-1.1%)0/25
- Financial Health100/100 · Strong
- Altman Z (43.08)25/25
- Current ratio (2.86)25/25
- Interest coverage (106.6x)25/25
- Net cash / debt (Net cash)25/25
- Quality47/100 · Weak
- Piotroski F (4/9)10/25
- Beneish M (-2.73)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 13.7%)12/25
About Corcept Therapeutics Inc.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. Show more
The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Headquarters: REDWOOD CITY, CA · Employees: 730 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOption exercise · filed 2026-08-28-30000 sh2026-08-26
- SellOpen market sale · filed 2026-08-28-26685 sh2026-08-26
- SellTax withholding · filed 2026-08-28-3315 sh2026-08-26
- BuyOption exercise · filed 2026-08-28+30.0K sh2026-08-26
- SellOption exercise · filed 2026-08-27-30955 sh2026-08-25
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)259.2xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 17.8x–272.6x · highest in history
P/FCF102.1xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield0.9%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: 0.9%–8.9% · lowest in history
P/S (TTM)16.51xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.7x–20.0x · highest in history
EV/EBITDA1485.3xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales15.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E61.4xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio19.91xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
18EROIC-2.2%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE7.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA6.6%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin6.2%C
Grade C: AverageNet Income / Revenue
Operating Margin-1.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin98.3%A
Grade A: PremiumGross Profit / Revenue
FCF Margin15.6%A
Grade A: HighFCF / Revenue
True FCF Margin4.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
100A+Altman Z-Score43.08A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.86xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.71xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage106.6xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
50CRevenue CAGR20.1%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-3.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-1.8%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth322.3%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-19.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income181.0%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue11.1%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
47D+Piotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.73A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability13.7%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue0.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.91xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$0.45
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.56
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.11
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$338.18M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$637.99M
Shareholders' equity (book value)
Asset / Liability4.61xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$12.70B
Current Market Capitalization
Beta0.49B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Neutral
Company is effectively debt-free after netting cash. · Current P/E of 259.2x is the highest in available history.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 23, 2026
Key Insights: Corcept Therapeutics Inc. (CORT)
Composite verdict for Corcept Therapeutics Inc.: Neutral. Piotroski F-Score of 4/9 indicates mixed fundamentals for Corcept Therapeutics Inc.. Altman Z-Score of 43.08 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.73 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 20% annually — a strong growth profile.
- Corcept Therapeutics Inc. converts about 16% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- At a valuation score of 20/100, CORT trades at a premium to its historical multiples (P/E 259.2).
See how CORT ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all CORT moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 22 | Regular | 118.20 | +3.90% | 2.09 |
| Sep 21 | Regular | 113.98 | +3.35% | 2.23 |
| Sep 21 | After-hours | 113.76 | +3.15% | 2.10 |
Frequently Asked Questions about CORT
Is CORT stock a buy right now?
PreMarketPrice's quantitative model rates Corcept Therapeutics Inc.'s financial health at 100/100 — Neutral. This is a data-driven snapshot of fundamentals, not investment advice.
Is CORT stock overvalued?
Corcept Therapeutics Inc. trades at a trailing P/E of 259.2 and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Corcept Therapeutics Inc. report earnings?
No confirmed earnings date is currently scheduled for CORT. The Earnings section lists recent reports and updates as dates are announced.
What sector does Corcept Therapeutics Inc. operate in?
Corcept Therapeutics Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Corcept Therapeutics Inc. do?
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone.
About Corcept Therapeutics Inc. (CORT) Stock
Corcept Therapeutics Inc. (CORT) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. Real-time pricing data for Corcept Therapeutics Inc. is available on this page with a market capitalization of $12.7 billion. The financial health score for CORT is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CORT stock.
CORT Stock Analysis & Key Metrics
On PreMarketPrice, you can track Corcept Therapeutics Inc. (CORT) across multiple dimensions:
- Pre-market price & movement: Real-time CORT stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CORT with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Corcept Therapeutics Inc. across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CORT.
- Sector peers: Compare CORT against 10 other healthcare stocks on key financial metrics.
Is CORT a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Corcept Therapeutics Inc. (CORT) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Corcept Therapeutics Inc. (CORT) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.